Ethical perspectives on pharmacogenomic profiling in the drug development process

Nature Reviews Drug Discovery

Volumn 1, Issue 4, 2002, Pages 300-308

  Issa, Amalia M ^a,b  

^a SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIHYPERTENSIVE AGENT; CLOZAPINE; GENERIC DRUG; MONTELUKAST; NEW DRUG; OMEPRAZOLE; ORPHAN DRUG; PRAVASTATIN; TACRINE; ZILEUTON;

ALZHEIMER DISEASE; ARTICLE; ASTHMA; CLINICAL PRACTICE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; COST EFFECTIVENESS ANALYSIS; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG MARKETING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; ECONOMIC ASPECT; EXPERIMENTAL DESIGN; GASTRODUODENAL ULCER; GENE EXPRESSION PROFILING; GENETIC POLYMORPHISM; HUMAN; PHARMACOGENOMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIAL ASPECT; BIOMEDICAL AND BEHAVIORAL RESEARCH; DRUG DESIGN; ECONOMICS; ETHICS; GENETICS AND REPRODUCTION; GENOMICS; METHODOLOGY; PHARMACOGENETICS; REVIEW;

BIOMEDICAL AND BEHAVIORAL RESEARCH; GENETICS AND REPRODUCTION;

CLINICAL TRIALS; DRUG DESIGN; ETHICS; GENOMICS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; RESEARCH DESIGN;

EID: 0036527287     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd771     Document Type: Article

References (70)

1. Evans, W. E. & Relling, M. V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286, 487-491 (1999).
2. Rioux, P. P. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am. J. Health Syst. Pharm. 57, 887-898 (2000).
3. McLeod, H. F. & Evans, W. E. Pharmacogenomics: unlocking the human genome for better drug therapy. Annu. Rev. Pharmacol. Toxicol. 41, 101-121 (2001).
4. Norton, R. M. Clinical pharmacogenomics: applications in pharmaceutical R & D. Drug Discov. Today 6, 180-185 (2001).
5. Classen, D. C., Pestotnik, S. L., Evans, R. S. & Lloyd, J. F. Adverse drug events in hospitalized patients. Excess length of stay, extra costs, and attributable mortality. JAMA 277, 301-306 (1997).
6. Lazarou, J., Pomeranz, B. H. & Corey, P. N. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279, 1200-1205 (1998).
7. Phillips, K. A., Veenstra, D. L., Oren, E., Lee, J. K. & Sadee, W. Potential role of pharmacogenomics in reducing adverse drug reactions. JAMA 286, 2270-2279 (2001).
8. Primohamed, M. & Park, B. K. Genetic susceptibility to adverse drug reactions. Trends Pharmacol. Sci. 22, 298-305 (2001).
9. Persidis, A. Pharmacogenomics. Nature Biotechnol. 18, IT40-IT42 (2000).
10. Arledge, T., Freeman, A., Arbuckle, J., Mosteller, M. & Manasco, P. Applications of pharmacogenetics to drug development: the Glaxo Wellcome experience. Drug Metab. Rev. 32, 387-394 (2000).
11. Furuta, T. et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin. Pharmacol. Ther. 69, 158-168 (2001).
12. Lessard, E. et al. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans. Pharmacogenetics 9, 435-443 (1999).
13. Drazen, J. M. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170 (1999).
14. Israel, E. et al. Effect of polymorphism of the β(2)-adrenergic receptor on response to regular use of albuterol in asthma. Int. Arch. Allergy Immunol. 124, 183-186 (2001).
15. Poiner, J. et al. Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc. Natl Acad. Sci. USA 92, 12260-12264 (1995).
16. Richard, F. et al. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349, 539-540 (1997).
17. Rigaud, S. et al. The apolipoprotein E4 allele and the response to tacrine therapy in Alzheimer's disease. Eur. J. Neurol. 7, 255-258 (2000).
18. 2A receptor gene. Lancet 346, 281-282 (1995).
19. Masellis, M. et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacol. 19, 123-132 (1998).
20. 2A gene and schizophrenia: relation to phenotype and drug response variability. J. Psych. Neurosci. 24, 141-146 (1999).
21. Kuivenhoven, J. A. et al. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl. J. Med. 338, 86-93 (1998).
22. Drazen, J. M. et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nature Genet. 22, 168-170 (1999).
23. World Health Organization. Proposed International Guidelines on Ethical Issues in Medical Genetics and Genetics Services (1997).
24. Holtzman, N. A. & Watson, M. S. (eds) Promoting Safe and Effective Genetic Testing in the United States: Final Report of the Task Force on Genetic Testing (National Institutes of Health - Department of Energy Working Group on Ethical, Legal and Social Implications of Human Genome Research Task Force on Genetic Testing, Washington DC, 1997).
25. Secretary's Advisory Committee on Genetic Testing. Enhancing the Oversight of Genetic Tests: Recommendations of the SACGT (2000).
26. Robertson, J. A. Consent and privacy in pharmacogenetic testing. Nature Genet. 28, 207-209 (2001).
27. Issa, A. M. Ethical considerations in clinical pharmacogenomics research. Trends Pharmacol. Sci. 21, 247-250 (2000).
28. Title 45, US Code of Federal Regulations (CFR), part 46. Protection of human subjects, 45CFR46.111(a)(1) http://ohrp.osophs.dhhs.gov/.
29. Friedman, L. M., Furberg, C. D. & DeMets, D. L. Fundamentals of Clinical Trials (Wright, Boston, 1996).
30. Council for International Organizations of Medical Sciences. International Ethical Guidelines for Biomedical Research Involving Human Subjects (Geneva, 1993).
31. Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans. A Report by a Working Group of the Three Federal Funding councils: Medical Research Council of Canada, Natural Sciences and Engineering Research Council of Canada, and Social Sciences and Humanities Research Council of Canada (1998).
32. World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects, Adopted by the 18th WMA GeneralAssembly Helsinki, Finland, 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland (2000).
33. Emmanuel, E., Wendler, D. & Grady, C. What makes clinical research ethical? JAMA 283, 2701-2711 (2000).
34. Murphy, M. P. et al. Prospective CYP2D6 genotyping as an exclusion criterion for enrolment of a Phase III clinical trial. Pharmacogenetics 10, 583-590 (2000).
35. Weber, W. W. Pharmacogenetics (Oxford Univ. Press, New York, 1997).
36. March, R. Pharmacogenomics: the genomics of drug response. Yeast 17, 16-21 (2000).
37. Silverman, E. K. & Palmer, L. J. Case-control association studies for the genetics of complex respiratory diseases. Am. J. Respir. Cell. Mol. Biol. 22, 645-648 (2000).
38. Bird, T. D., Jarvik, G. P. & Wood, N. W. Genetic association studies: genes in search of diseases. Neurology 57, 1153-1154 (2001).
39. Roden, D. M. & George, A. L. The genetic basis of variability in drug responses. Nature Rev. Drug Discov. 1, 37-44 (2002).
40. McCarthy, J. J. & Hilfiker, R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nature Biotechnol. 18, 505-508 (2000).
41. Carbon, L. R., Idury, R. M. & Harris, T. J. R. Testing drug response in the presence of genetic information: sampling issues for clinical trials. Pharmacogenetics 10, 503-510 (2000).
42. Long, A. D. & Langley, C. H. The power of association studies to detect the contribution of candidate genetic loci to variation in complex traits. Genome Res. 9, 720-731 (1999).
43. Blacker, D. α2-Macroglobulin is genetically associated with Alzheimer disease. Nature Genet. 19, 357-360 (1998).
44. Dow, D. J. et al. α2-Macroglobulin polymorphism and Alzheimer disease risk in the UK. Nature Genet. 22, 16-17 (1999).
45. Rudransingham, V. et al. α2-Macroglobulin gene and Alzheimer disease. Nature Genet. 22, 17-19 (1999).
46. Rogaeva, E. A. et al. An α2-Macroglobulin insertion-deletion polymorphism in Alzheimer disease. Nature Genet. 22, 19-21 (1999).
47. Editorial. Freely associating. Nature Genet. 22, 1-2 (1999).
48. Butler, D. Epidemiology set to get fast-track treatment. Nature 414, 139 (2001)
49. Albert, S. M., Sano, M. & Marder, K. Participation in clinical trials and long-term outcomes in Alzheimer's disease. Neurology 49, 38-43 (1997).
50. Knopman, D. et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 47, 166-177 (1996).
51. Issa, A. M. & Keyserlingk, E. W. Apolipoprotein E genotyping for pharmacogenetic purposes in Alzheimer's disease: emerging ethical issues. Can. J. Psychiatry 45, 917-922 (2000).
52. Sterne, J. A. C. Sifting the evidence - what's wrong with significance tests? Br. Med. J. 322, 226-231
53. Becker, R. E. Modifying clinical trial designs to test treatments for clinical significance in individual patients. Clin. Drug Invest. 21, 727-733 (2001).
54. Chen, S. et al. A genetic bias in clinical trials? Cytochrome P450-2D6 (CYP2D6) genotype in general vs selected healthy subject populations. Br. J. Clin. Pharmacol. 44, 303-304 (1997).
55. Bodenheimer, T. Uneasy alliance: clinical investigators and the pharmaceutical industry. New Engl. J. Med. 342, 1539-1544 (2000).
56. Zhao, H. Y. Family-based association studies. Stat. Methods Med. Res. 9, 563-587 (2000).
57. Jorde, L. B. Linkage disequilibrium and the search for complex disease genes. Genome Res. 10, 1435-1444 (2000).
58. Carbon, L. R. & Bell, J. L. Association study designs for complex diseases. Nature Rev. Genet. 2, 91-99 (2001).
59. Regaldo, A. Inventing the pharmacogenomics business. Am. J. Health Syst. Pharm. 56, 40-50 (1999).
60. Persidis, A. The business of pharmacogenomics. Nature Biotechnol. 16, 209-210 (1998).
61. Fogarty, M. Up for adoption: pharmacogenetics and the orphan drug law. HMS Beagle [online] (cited 01 Mar. 02) http://www.biomednet.com/hmsbeagle/44/op_ed.htm (1998).
62. Food and Drug Administration. Miscellaneous provisions relating to the Orphan Drug Act. Food and Drug Administrabon (cited 01 Mar 02) htpp://www.fda.gov/opacom/laws/orphandg.htm (2001).
63. National Organization for Rare Diseases (NORD). Understanding the Orphan Drug Act (cited 01 Mar 02) http://www.rarediseases.org/cgi-bin/nord (2001).
64. Europarliament. Scientific and Technological Options Assessment. Orphan Drug Status Initiatives in the Different Countries (cited 01 Mar 02) http://www.europarl.eu.int/home/default_en.htm.
65. Moses, H. & Martin, J. B. Academic relationships with industry: a new model for biomedical research. JAMA 285, 933-935 (2001).
66. Bains, W. The long-term value of genomics companies, J. Chem. Technol. Biotechnol. 75, 883-900 (2000).
67. Aronowitz, R. A. Making Sense of Illness: Science, Society and Disease. (Cambridge Univ. Press, Cambridge, UK, 1998).
68. Todd, J. A. Interpretation of results from genetic studies of multifactorial diseases. Lancet 354 (Suppl. 1), 15-16 (1999).
69. Patino, C. M. & Martinez, F. D. Interactions between genes and environment in the development of asthma. Allergy 56, 279-286 (2001).
70. Ingelman-Sundberg, M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Int. Med. 250, 186-200 (2001).